Interleukin strikes deals for genetic tests
This article was originally published in Clinica
In a move to bulk up its portfolio, Interleukin Genetics, the Waltham, Massachusetts-based developer of genetic tests for the personalised health market, is teaming up with healthcare services provider Geisinger Health System to develop products for predicting an individual's genetic predisposition to weight loss success. The two companies will carry out a case-control retrospective study involving the analysis of DNA to better understand the genetic links to obesity. The study will focus exclusively on variations of perilipin, interleukin 1 and a select number of other genes.